|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy.
|
30696811 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
|
31156179 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, substituting a single lysine residue in the context of a P301S disease-linked mutation produces a unique tau species that abrogates some of the cardinal features of tauopathy.
|
31543505 |
2019 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.
|
29126071 |
2018 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To explore this interaction in vivo, we crossed a well-characterized human P301S-tau transgenic mouse model of tauopathy with human G2019S-LRRK2 transgenic mice or LRRK2 knockout (KO) mice.
|
29088368 |
2018 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MFGE8 expression is elevated in transgenic P301S-tau mouse brains with tau inclusions and in tau inclusion-rich brain regions of several human tauopathies, indicating shared mechanisms of disease.
|
30134156 |
2018 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Tau silencing by siRNA in the P301S mouse model of tauopathy.
|
25687501 |
2014 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The present study examined the effects of MB in the P301S mouse model of tauopathy.
|
24556215 |
2014 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The P301S mutation in exon 10 of the tau gene causes a hereditary tauopathy.
|
25437199 |
2014 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We further demonstrate that peripheral administration of the same antibodies in the more rapidly progressive P301S tauopathy model not only reduces Tau pathology quantitated by biochemical assays and immunohistochemistry, but also significantly delays the onset of motor function decline and weight loss.
|
21841002 |
2011 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating.
|
21698260 |
2011 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mice transgenic for human P301S tau protein exhibit many characteristics of human tauopathies, including neurodegeneration, the formation of neuronal tau inclusions in the brain and the development of a pronounced motor phenotype by 5 months of age.
|
20004218 |
2010 |
|
rs63751438
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, transgenic mice expressing mutant (for example, P301S) human tau in nerve cells show the essential features of tauopathies, including neurodegeneration and abundant filaments made of hyperphosphorylated tau protein.
|
19503072 |
2009 |